Data were collected from surgical patients in the hospital and on 4 occasions postdischarge. The incidence of postdischarge surgical site infection was 8.46%. Strong evidence showed that these infections caused minor additional costs, which contradicts existing literature. We discuss why previous studies might have overstated costs. M ost cases of healthcare-acquired surgical site infections (SSI) appear after discharge from hospital (1); rates of postdischarge SSI between 2% and 14% have been reported (2). Little is known of the costs of postdischarge SSI, but 2 studies suggest that they are large (3-5) with health services and patients incurring costs and subsequent production losses. The combination of high frequency and high cost suggests that programs that reduce the risks of postdischarge SSI should be adopted, but decision makers should assess the cost-effectiveness of additional prevention efforts. This exercise requires valid estimates of the change in costs and benefits from additional prevention programs (6,7). Understanding the costs of postdischarge SSI is therefore essential. The work completed so far is valuable but demonstrates some methodologic weaknesses. Plowman et al. (3, 4) assessed only patient-reported signs and symptoms of postdischarge SSI, and Perencevich et al. (5) relied on routine healthcare records for diagnosis/surveillance and matched case patients with controls on only 3 confounding variables.
M ost cases of healthcare-acquired surgical site infections (SSI) appear after discharge from hospital (1); rates of postdischarge SSI between 2% and 14% have been reported (2) . Little is known of the costs of postdischarge SSI, but 2 studies suggest that they are large (3) (4) (5) with health services and patients incurring costs and subsequent production losses. The combination of high frequency and high cost suggests that programs that reduce the risks of postdischarge SSI should be adopted, but decision makers should assess the cost-effectiveness of additional prevention efforts. This exercise requires valid estimates of the change in costs and benefits from additional prevention programs (6, 7) . Understanding the costs of postdischarge SSI is therefore essential. The work completed so far is valuable but demonstrates some methodologic weaknesses. Plowman et al. (3, 4) assessed only patient-reported signs and symptoms of postdischarge SSI, and Perencevich et al. (5) relied on routine healthcare records for diagnosis/surveillance and matched case patients with controls on only 3 confounding variables.
Our study assessed the costs of postdischarge SSI. We adopted a societal perspective and included the costs incurred by healthcare services, private costs, and production losses. The research method was chosen to address the suggested weaknesses of the studies of Plowman et al. (3, 4) and Perencevich et al. (5) .
The Study
We recruited, in consecutive order, adults (>18 years of age) admitted to 3 Australian hospitals in 2004 for knee or hip prostheses, cardiovascular procedures, femoropopliteal bypass grafts, or abdominal procedures, including abdominal hysterectomies and lower segment caesarean sections. Four infection-control research nurses recruited participants and collected data during the hospital admission process and on 4 separate occasions after surgery by visiting the patients in their homes (data collection is illustrated in the Figure) . Monetary estimates of all costs were made by multiplying frequency with a cost vector for the item of service (9) (10) (11) (12) . Production losses were estimated by comparing the presurgery level of (unwaged and waged) productive activity with the actual level of (unwaged and waged) productive activity achieved during the 4 weeks postdischarge. These losses were converted to a monetary value by using market prices for labor, approximated by average pretax earnings (13) .
The question we address is whether postdischarge SSIs independently affect costs. The specific cost outcomes we seek to explain are listed in online Appendix 1 (available from http://www.cdc.gov/ncidod/EID/vol12no05/05-1321 _app1.htm). Adjustment was made for other factors believed to influence these cost outcomes (i.e., confounding factors); these included the type of surgical procedure, duration of surgery, American Society of Anesthesiologists score, wound class, number of coexisting conditions, length of hospital stay, whether patient was funded by the public sector or private insurance, admitting hospital, sex, age, ethnicity, patient's socioeconomic status (14) , whether the patient was in waged employment, salary level and health-related quality of life as measured by the SF-12v2 Health Survey (available from http://www.sf-36.org/ tools/sf12.shtml) scores at baseline and 4 weeks postdischarge. The complete set of explanatory variables available for analyses and the summary statistics are presented in Table 1 and online Appendix 2 (available at http:// www.cdc.gov/ncidod/EID/vol12no05/05-1321_app2 .htm). Because the outcome variables were continuous and linear, ordinary least squares regression was chosen to model the independent effect of SSI on cost outcomes (Table 2 ). See online Appendix 3 (available at http://www. cdc.gov/ncidod/EID/vol12no05/05-1321_app3.htm) for a description of the statistical analyses.
The mean age of the 449 patients included in the analyses was 63.65 years (SD 14.34), and 50.56% were women. The mean length of hospital stay for the sample was 7.8 days (SD 8.68, median 6 days, interquartile range 4-8). Thirty-eight of the 449 patients included in the study had a diagnosis of SSI postdischarge, which indicates an incidence of 8.46% for the 8-month period during which patients were recruited. A higher proportion of persons with SSI (18.24%) compared to those without SSI (2.43%) were readmitted to the hospital, but the mean lengths of stay of the readmitted persons were similar, 16.57 days versus 15.72 days, respectively. Summary statistics for all variables are included in Table 1 and in online Appendix 2, and the ICD-10 procedures for the 38 cases of SSI are described in online Appendix 4 (available at http://www. cdc.gov/ncidod/EID/vol12no05/05-1321_app4.htm).
No evidence was found of multicollinearity or interactions between variables. However, none of the outcome variables were normally distributed, and variance of the error term was not constant (i.e., heteroscedastic), so all models were estimated by using the Huber-White covariance matrix (15) . Results of the ordinary least squares regressions are summarized in online Appendix 1. Strong statistical evidence shows that postdischarge SSI independently causes the following: 1.36 extra contacts with community-based services with increased costs of $47.78; 6.46 days of additional antimicrobial drug therapy with increased costs of $14.44; and an increase in total health service costs of AU $74 (US $57) when the costs of readmission to the hospital are excluded and AU $123 (US $94) when the costs of readmission to the hospital are included. The strength of the relationship between SSI and all other cost outcomes was not significant with the 95% confidence interval crossing zero for all other models. 
Conclusions
These results support the view that most SSIs first appear after discharge from hospital, but we did not find any evidence that postdischarge SSI causes substantial economic costs even when costs are viewed from a societal perspective. These findings contradict Perencevich et al. (5), who found the economic cost of a case of SSI diagnosed after discharge was almost 50-fold the estimate we report here. Thus, what might explain this extreme discrepancy in attributed costs? The study designs and research methods differed. Compared to Perencevich et al. (5), we used more control variables (described in Tables 1 and  Online Appendix 2 and listed below the table in Appendix  1) . Might this extended set of control variables reduce bias from omitted variables and so reduce the cost attributed to SSI? Another factor might be the surveillance method. Perencevich et al. (5) used automated record screening that relied on accurate documentation of diagnostic, testing, or treatment codes and pharmacy records. This process resulted in 89 diagnoses among 4,571 patients, an incidence rate of 1.9%. For our study, patients were recruited before surgery and infection-control research-nurses visited the patients in their homes on 4 occasions after discharge, during which time the wound was examined and the definition of the Centers for Disease Control and Prevention definition, modified by the Australian Infection Control Association Inc., was applied (8) . This method yielded a much higher infection rate of 8.38%. One interpretation is that the surveillance method used by Perencevich et al. was not sensitive to all cases of postdischarge SSI. Instead, only those that generated certain data items in the downstream electronic records were flagged, and these may have been the most serious cases of SSI that generated the greatest costs. This theory might be supported by the higher rate of readmission among the patients with cases of SSI in the Perencevich data (34%) compared to the rate in our study (18%).
Of course, other factors may have an influence, such as the case mix and socioeconomic characteristics of the participants, the costs of the inputs to healthcare services (i.e., salaries for doctors and nurses), consumer preferences (i.e., for more or less postdischarge care), and predefined care protocols. Also, our data only describe a 4-week period after surgery and not the 8-week period considered by Perencevich et al. (5) . We recommend that readers interpret our results carefully but nevertheless suggest that the economic costs of SSIs that occur after hospital discharge are real but not substantial.
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